Clinical Trial Update: The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis [Phase 3]

View source ↗

Summary

Phase 3 trial of NEOD001 for AL amyloidosis was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Amyloidosis

Drugs mentioned

• NEOD001 (NEOD001)

Snippet

Sponsor: Prothena Biosciences Ltd. | Conditions: Primary Systemic (AL) Amyloidosis | Phase 3 | Status: TERMINATED | Results posted: 2019-05-29